277 related articles for article (PubMed ID: 27233379)
1. Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer.
De Marchi T; Foekens JA; Umar A; Martens JW
Drug Discov Today; 2016 Jul; 21(7):1181-8. PubMed ID: 27233379
[TBL] [Abstract][Full Text] [Related]
2. Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
Giuliano M; Schifp R; Osborne CK; Trivedi MV
Breast; 2011 Oct; 20 Suppl 3():S42-9. PubMed ID: 22015292
[TBL] [Abstract][Full Text] [Related]
3. What clinicians need to know about antioestrogen resistance in breast cancer therapy.
Milano A; Dal Lago L; Sotiriou C; Piccart M; Cardoso F
Eur J Cancer; 2006 Nov; 42(16):2692-705. PubMed ID: 16963260
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of tamoxifen resistance.
Ring A; Dowsett M
Endocr Relat Cancer; 2004 Dec; 11(4):643-58. PubMed ID: 15613444
[TBL] [Abstract][Full Text] [Related]
5. Nuclear and extranuclear-initiated estrogen receptor signaling crosstalk and endocrine resistance in breast cancer.
Kulkoyluoglu E; Madak-Erdogan Z
Steroids; 2016 Oct; 114():41-47. PubMed ID: 27394959
[TBL] [Abstract][Full Text] [Related]
6. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
Alfarsi LH; Elansari R; Toss MS; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Jan; 173(1):93-102. PubMed ID: 30306428
[TBL] [Abstract][Full Text] [Related]
7. Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies.
Roop RP; Ma CX
Future Oncol; 2012 Mar; 8(3):273-92. PubMed ID: 22409464
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers.
Nahta R; O'Regan RM
Breast Cancer Res Treat; 2012 Aug; 135(1):39-48. PubMed ID: 22527112
[TBL] [Abstract][Full Text] [Related]
9. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836
[TBL] [Abstract][Full Text] [Related]
10. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
11. Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer.
Nagaraj G; Ma C
Breast Cancer Res Treat; 2015 Apr; 150(2):231-42. PubMed ID: 25762475
[TBL] [Abstract][Full Text] [Related]
12. Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer.
Alfarsi L; Johnston S; Liu DX; Rakha E; Green AR
Histopathology; 2018 Oct; 73(4):545-558. PubMed ID: 29603357
[TBL] [Abstract][Full Text] [Related]
13. Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers.
Selli C; Dixon JM; Sims AH
Breast Cancer Res; 2016 Dec; 18(1):118. PubMed ID: 27903276
[TBL] [Abstract][Full Text] [Related]
14. p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study.
Kai K; Nishimura R; Arima N; Miyayama H; Iwase H
Int J Clin Oncol; 2006 Dec; 11(6):426-33. PubMed ID: 17180510
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy in luminal breast cancers.
Lim E; Winer EP
Breast; 2011 Oct; 20 Suppl 3():S128-31. PubMed ID: 22015279
[TBL] [Abstract][Full Text] [Related]
16. Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer.
Reinert T; de Paula B; Shafaee MN; Souza PH; Ellis MJ; Bines J
Chin Clin Oncol; 2018 Jun; 7(3):25. PubMed ID: 30056727
[TBL] [Abstract][Full Text] [Related]
17. A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses.
Clusan L; Le Goff P; Flouriot G; Pakdel F
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33451133
[TBL] [Abstract][Full Text] [Related]
18. The changing role of ER in endocrine resistance.
Nardone A; De Angelis C; Trivedi MV; Osborne CK; Schiff R
Breast; 2015 Nov; 24 Suppl 2(0 2):S60-6. PubMed ID: 26271713
[TBL] [Abstract][Full Text] [Related]
19. Reliability of estrogen receptors in predicting response to antiestrogens.
Valavaara R
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):14-8. PubMed ID: 9165501
[TBL] [Abstract][Full Text] [Related]
20. Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals.
Szostakowska M; Trębińska-Stryjewska A; Grzybowska EA; Fabisiewicz A
Breast Cancer Res Treat; 2019 Feb; 173(3):489-497. PubMed ID: 30382472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
